Adults

Usually 1 tablet (Olmesartan 20 mg / Amlodipine 5 mg) orally once daily. Dosage may be titrated up to a maximum of 40 mg / 10 mg once daily based on blood pressure response.

Elderly

No special dosage adjustment is usually required, but caution is advised, and lower starting doses may be considered, especially for Amlodipine.

Renal_impairment

No dosage adjustment is needed for mild to moderate renal impairment. Caution is advised in severe renal impairment.

Onset

Onset of action for blood pressure lowering is within 1-2 hours for both, but maximum effect might take 1-2 weeks of consistent dosing.

Excretion

Olmesartan: Approximately 30-50% renally and the remainder via hepatic/biliary excretion. Amlodipine: Primarily excreted via the kidneys (inactive metabolites).

Half life

Olmesartan: Approximately 13 hours. Amlodipine: Approximately 30-50 hours.

Absorption

Olmesartan medoxomil is rapidly and completely absorbed from the gastrointestinal tract and rapidly converted to olmesartan. Bioavailability is approximately 26%. Amlodipine is well absorbed after oral administration, with peak plasma concentrations reached 6-12 hours post-dose. Absolute bioavailability is estimated to be 64-90%.

Metabolism

Olmesartan: Negligibly metabolized. Amlodipine: Extensively metabolized in the liver to inactive metabolites (CYP3A4).

NSAIDs

Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect of Olmesartan and increase the risk of renal impairment.

Simvastatin

Coadministration with Amlodipine may increase Simvastatin exposure. Limit Simvastatin dose to 20 mg daily.

CYP3A4 Inducers (e.g., Rifampicin)

May decrease Amlodipine exposure, potentially reducing its effectiveness.

Potassium-sparing diuretics/Potassium supplements

May increase serum potassium levels when used with Olmesartan.

CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole)

May increase Amlodipine exposure, leading to increased risk of hypotension.